← Quoin Pharmaceuticals, Ltd. (QNRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Quoin Pharmaceuticals, Ltd. (QNRX)
Pharmaceutical Preparations · market cap $14M · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Quoin Pharmaceuticals (QNRX) is a micro-cap specialty pharma with 3 employees and a market cap of ~$15.8B (implied by ~3.35B shares at $4.72) focused entirely on QRX003, a lotion formulation targeting Netherton Syndrome, a rare skin disorder. The company has $3.1M cash, roughly 1.9 months of runway, and a pivotal Phase 3 readout for its 4% formulation expected around July 30, 2026. The company has no revenue history and has burned approximately $9-16M annually in recent years.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| QRX003, 4% Lotion | Phase 3 | Netherton Syndrome |
| QRX003-2% Lotion | Phase 3 | Netherton Syndrome |
Price & technical context
3-month
+3.1%
6-month
-22.1%
12-month
-34.4%
52-wk range
$3.25–$22.30
vs 50-day MA
-16.6%
vs 200-day MA
-32.5%
Realized vol
157.7%
Max drawdown
-90.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for QNRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.